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Five highly amikacin-resistant Acinetobacter baumannii isolates were collected at a medical center in Penn-
sylvania. The aminoglycoside resistance was due to the production of the 16S rRNA methylase ArmA. Two of
the isolates coproduced OXA-23 -lactamase and were highly resistant to carbapenems as well. The isolates
were genetically closely related by pulsed-field gel electrophoresis.
Acinetobacter baumannii is increasingly becoming a major
nosocomial pathogen worldwide, particularly in the setting of
ventilator-associated pneumonia or bloodstream infections in
intensive care units (6). The treatment is complicated by its
tendency to acquire resistance to multiple classes of antimicro-
bials (2). When these strains are encountered, empirical sal-
vage regimens may include such agents as colistin, tigecycline,
and amikacin (1, 13). Amikacin is an aminoglycoside that gen-
erally continues to retain good activity against A. baumannii (3,
11). Resistance to amikacin in A. baumannii is primarily me-
diated by structural modification of the agent through the
actions of aminoglycoside-modifying enzymes that are pro-
duced by resistant strains (14). In recent years, the production
of 16S rRNA methylases has been implicated in aminoglyco-
side resistance among gram-negative pathogens (4). Five such
enzymes have been identified, ArmA and RmtA through -D.
They confer high-level resistance to all parenterally formulated
aminoglycosides, effectively eliminating the entire class, includ-
ing amikacin, as a therapeutic option. The presence of these
16S rRNA methylases has already been reported worldwide,
but no strains with this resistance mechanism have been re-
ported in North America so far.
Between December 2006 and March 2007, five nonrepetitive
A. baumannii isolates (isolates A through E) with high-level
resistance to amikacin, tobramycin, and gentamicin (defined by
MICs of 512 g/ml) were recovered from inpatients at the
University of Pittsburgh Medical Center. Multiplex PCR for
the five known 16S rRNA methylase genes (4) yielded ampli-
cons consistent with armA for all five isolates, which was ver-
ified by sequencing. No amplicons were obtained for the other
16S rRNA methylase genes. In addition, isolates A and B, both
of which were highly resistant to carbapenems, were posi-
tive for blaOXA-23 by PCR and sequencing (5). OXA-23 is a
carbapenem-hydrolyzing -lactamase that is known to cause
clinically relevant carbapenem resistance (10).
The genomic DNA of isolate B was then prepared, digested
with HindIII (New England BioLabs, Beverly, MA), and li-
gated with cloning vector pUC19. Electrocompetent Esche-
richia coli DH10B (Invitrogen Corporation, Carlsbad, CA) was
transformed with the resultant recombinant plasmids. As a
result, pUCarmA, a pUC19 derivative with a 4-kb insert con-
taining armA, was obtained. E. coli DH10B(pUCarmA) exhib-
ited high-level resistance (MICs, 256 g/ml) to amikacin,
tobramycin, and gentamicin. The genetic environment sur-
rounding armA was identical to those reported earlier as
Tn1548 for strains belonging to the family Enterobacteriaceae
(7, 8). The 3 end of orf513, the gene that encodes a putative
transposase that characterizes ISCR1 and that is commonly
associated with class 1 integrons (16), and tnpU, another pu-
tative transposase gene, were located upstream of armA. It was
followed downstream by the 5 end of yet another putative
transposase gene, tnpD. These findings suggest that Tn1548 is
serving as an efficient vehicle to mobilize armA across phylo-
genetically distant gram-negative species.
A reverse transcription assay was conducted to confirm the
expression of armA in A. baumannii. Total RNAs of isolate B
(armA positive) and isolate F (armA negative) were prepared
with the RNeasy Maxi kit (QIAGEN Inc., Valencia, CA).
Reverse transcription was performed by the use of a high-
capacity cDNA reverse transcription kit (Applied Biosystems).
The resultant cDNA was then used as the template for a PCR
(4). The presence of mRNA transcripts for armA was observed
in isolate B (armA positive) but not isolate F (armA negative).
No amplicon was obtained for either isolate when reverse
transcriptase was absent. These results confirmed the expres-
sion of armA in A. baumannii.
Curing of armA was attempted with A. baumannii isolate B
by serial passage of the strain in Luria-Bertani broth contain-
ing ethidium bromide at a subinhibitory concentration. One of
the strains obtained by this procedure, A. baumannii 231, was
found to be susceptible to amikacin. Loss of armA was con-
firmed by PCR. Conjugation experiments were conducted with
the five study isolates as the donors and azide-resistant E. coli
J53 or colistin-resistant A. baumannii 213 as the recipient by
using standard broth mating techniques. No amikacin-resistant
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transconjugants were obtained for any of the study isolates
producing ArmA with either recipient.
To further localize the armA gene, both plasmid and
genomic DNAs from isolate A were subjected to DNA hybrid-
ization. Plasmids from isolate A were extracted and subjected
to electrophoresis. Subsequently, they were transferred to a
nylon membrane by the method of Southern (15) and hybrid-
ized with digoxigenin-labeled armA gene fragments by use of
the PCR DIG detection system (Roche Diagnostics, Indiana-
polis, IN). The genomic DNA of isolate A was digested with
restriction enzyme CeuI (New England BioLabs) and sub-
jected to pulsed-field gel electrophoresis (PFGE) according to
the method of Liu et al. (12). Hybridization was carried out
in the same fashion by using probes specific for either armA or
the 16S and 23S rRNA genes (9). A plasmidic band from
isolate A hybridized with the armA probe, whereas none of the
chromosomal bands obtained by CeuI digestion hybridized
with it. These results, along with the curability of armA, sug-
gested a plasmidic location of armA.
To assess the genetic relatedness of the study isolates,
genomic DNA was isolated and digested with ApaI (New
England BioLabs). PFGE was performed with the CHEF III
system (Bio-Rad, Hercules, CA) with the following run param-
eters: block I, switch time of 3 to 8 s and run time of 10 h; block
II, switch time of 12 to 20 s and run time of 10 h. The five
isolates that carry armA were either identical or closely related
to each other, differing by up to three bands (Fig. 1). Thus, the
spread of armA in our study population appeared to be due to
the dissemination of closely related clones of A. baumannii that
carry armA on a nonconjugative plasmid.
In summary, we report the first identification of 16S rRNA
methylase as a mechanism of high-level resistance to aminogly-
cosides in North America. Some of the A. baumannii strains
were simultaneously resistant to other classes of antimicro-
bials, including carbapenems. More research is required to add
to the understanding of the increasingly complex nature of the
multidrug resistance in this troublesome organism.
Nucleotide sequence accession number. The nucleotide se-
quence determined in this study appears in the EMBL/GenBank/
DDBJ databases under accession number EU014811.
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FIG. 1. Result of PFGE. Lanes 1 and 8, molecular weight marker;
lanes 2 to 6, isolates A to E; lane 7, armA-negative, amikacin-resistant
clinical isolate from the study period (control).
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